

LETTERS TO THE EDITOR

Manifestations and predictors of vascular involvement in Behçet's disease

Pereira da Costa R^{1,2*}, Lucas Rocha M^{1,3*}, Martins-Martinho J^{1,2}, Teodósio Chicharo A^{1,3}, Macieira C¹, Ponte C^{1,2}, Khmelinskii N^{1,2}

Dear Editor,

Behçet's disease (BD) is a variable vessel vasculitis characterised by heterogeneous manifestations¹. Vascular involvement (VBD) most often affects the venous system, occurring in up to 15-40% of patients¹⁻⁴. Vascular manifestations are major predictors of morbidity and mortality in BD^{5,6}. However, predictors of VBD remain poorly defined.

Our aim was to characterise VBD patients and identify its predictors. We conducted a single-centre, retrospective study, including patients fulfilling the 2013 International Criteria for BD, registered in the Rheumatic Diseases Portuguese Registry (Reuma.pt) between October 2014 and May 2023^{7,8}. VBD was defined as an arterial or venous manifestation attributable to BD and confirmed by imaging (Doppler ultrasonography, computed tomography angiography, or magnetic resonance angiography), excluding ocular and central nervous system vascular involvement. Demographic and clinical characteristics were collected. Clinical manifestations were categorised as occurring at disease onset (within the first 12 months after symptom onset) or ever (at onset and/or at any time during follow-up). Comparisons were made using chi-squared, Fisher's exact, Mann-Whitney or t-test, with $p < 0.05$ considered significant. A multivariable logistic regression model with backward stepwise selection was performed to determine predictors of VBD.

We included 157 BD patients. VBD was present in 24 (15%) and was the inaugural manifestation in seven (5%). VBD developed at a median age of 36.0 years (IQR 10.0), 8.9 median years (IQR 16.7) after BD symptom onset. The most frequent symptoms were

limb pain (12/16, 75%), limb oedema (7/14, 50%) and thoracic pain (4/22, 18%). The venous system was more frequently involved than the arterial (20/24, 83% vs 10/24, 42%), with six patients exhibiting both. Venous involvement included deep vein thrombosis (12/24, 50%) and superficial thrombophlebitis (10/24, 42%). The lower limb veins were involved in all patients with venous disease (100%) and the inferior vena cava in one (5%). Arterial involvement included aneurysms (5/24, 21%), pulmonary thrombosis (3/24, 13%) and pseudoaneurysms (2/24, 8%). The pulmonary (4/10, 40%) and lower limb arteries (4/10, 40%) were most affected. Multiple-vessel involvement (13/24, 54%) and recurrent episodes (14/24, 58%) were frequent.

Disease characteristics of patients with BD with and without vascular involvement are presented in Table I. In univariable analysis, cutaneous manifestations at disease onset (OR 2.65, $p = 0.038$) and constitutional symptoms during follow-up (OR 2.81, $p = 0.046$) were associated with VBD, in addition to male sex and ocular involvement at onset (Table I). On multivariable analysis, only male sex (OR 3.99, 95%CI 1.55-10.28) and ocular involvement at disease onset (OR 3.90, 95%CI 1.29-11.72) remained independently associated with VBD (Table I). A sensitivity multivariable analysis excluding individuals with VBD at baseline identified male sex as the only independent predictor of this manifestation (OR 4.61, 95% CI 1.59-13.4; $p = 0.005$). Mortality did not significantly differ between groups (2/24, 8% vs 3/133, 2%; $p = 0.168$).

In summary, our cohort showed a 15% prevalence of VBD, with deep vein thrombosis being the predominant form. Male sex and ocular manifestations at disease onset emerged as independently associated with VBD. Previous studies consistently reported a higher frequency of VBD in males^{3,4,9,10}, while ocular manifestations were usually described as less common in this group^{3,4,9}. Associations with genital ulcers^{3,9}, gastrointestinal disease^{3,10}, erythema nodosum, cardiac and neurological involvement have been variably reported^{3,4,9,10}. Our findings reinforce male sex as an independent predictor of VBD but, in contrast to prior reports, identify an independent association between ocular involvement at disease onset and VBD. This difference may reflect a geographical variation in disease

* These authors share first authorship.

1. Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal;

2. Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisboa, Portugal;

3. Rheumatology Department, Unidade Local de Saúde do Algarve, Faro, Portugal.

Submitted: 02/10/2025

Accepted: 31/12/2025

Correspondence to: Roberto Pereira da Costa

E-mail: robertopc25@hotmail.com

TABLE I. Disease characteristics of patients with Behçet's disease with (VBD) and without (non-VBD) vascular involvement.

	All patients (N=157)	VBD patients (N=24)	Non-VBD patients (N=133)	p-value
Demographics				
Male gender, n (%)	41 (26)	12 (50)	29 (22)	0.004
Caucasian ancestry, n (%) ^θ	127 (88)	19 (83)	108 (90)	0.477
Age at symptom onset, mean±SD years ^θ	24.5±12.5	23.8±10.4	24.6±12.9	0.760
Age at BD diagnosis, mean±SD years ^θ	32.0±12.2	34.1±13.1	31.6±12.1	0.367
Diagnostic delay, median (IQR) years ^θ	3.0 (8.0)	4.9 (15.9)	2.0 (10.9)	0.277
Symptom duration, median (IQR) years ^θ	11.0 (11.8)	15.0 (24.0)	11.0 (10.0)	0.092
Manifestations at disease onset, n (%)				
Oral ulcers ^θ	136 (89)	21 (91)	115 (89)	1.000
Genital ulcers ^θ	59 (39)	8 (35)	51 (39)	0.686
Ocular manifestations ^{1θ}	21 (16)	7 (30)	14 (11)	0.020
Cutaneous manifestations ^{2θ}	39 (26)	10 (44)	29 (23)	0.034
Articular manifestations ^{3θ}	18 (12)	2 (9)	16 (12)	1.000
Neurological manifestations ^{4θ}	2 (1)	0 (0)	2 (2)	NA
Gastrointestinal manifestations ^{5θ}	1 (1)	0 (0)	1 (1)	NA
Constitutional symptoms ^θ	11 (7)	1 (4)	10 (8)	1.000
Manifestations at both disease onset and follow-up, n (%)				
Oral ulcer	152 (97)	24 (100)	128 (96)	NA
Genital ulcer	127 (81)	20 (83)	107 (81)	1.000
Ocular manifestations ¹	60 (38)	13 (54)	47 (35)	0.081
Cutaneous manifestations ^{2θ}	117 (75)	22 (92)	95 (72)	0.040
Articular manifestations ^{3θ}	71 (46)	8 (33)	63 (48)	0.193
Neurological manifestations ^{4θ}	24 (15)	5 (21)	19 (14)	0.537
Gastrointestinal manifestations ⁵	17 (11)	2 (8)	15 (11)	1.000
Constitutional symptoms	24 (15)	7 (29)	17 (13)	0.060
Positive pathergy test [▽]	33 (37)	5 (39)	28 (36)	1.000
Positive HLA-B51 haplotype [▽]	35 (44)	4 (36)	31 (45)	0.748
ISG, 1990 criteria fulfilment	122 (78)	21 (88)	101 (76)	0.210
ICBD, 2006 criteria fulfilment	146 (93)	24 (100)	122 (92)	0.217
Treatment during the disease course, n (%)				
Systemic glucocorticoids ^θ	126 (81)	20 (87)	106 (80)	0.572
csDMARD ^θ	100 (65)	17 (74)	83 (64)	0.350
bDMARD ^θ	22 (15)	5 (22)	17 (13)	0.334
Cyclophosphamide ^θ	12 (8)	5 (22)	7 (5)	0.020
Anticoagulation ^θ	11 (7.2)	8 (36)	3 (2)	<0.001
Prognosis, n (%)				
Mortality	5 (3)	2 (8)	3 (2)	0.168

Categorical variables are presented as frequencies and percentages, and continuous variables as means and standard deviations, or medians and interquartile ranges for variables with skewed distributions.

θ Missing data <10%; φ Missing data 10-20%; ▽ Missing data 25-50%.

BD, Behçet's disease; bDMARDs, biologic disease-modifying anti-rheumatic drugs; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; ICBD, International Criteria for Behçet's Disease; ISG, International Study Group for Behçet's; NA, not applicable; VBD, Behçet's disease with vascular involvement.

¹ Ocular manifestations included anterior and/or posterior uveitis, retinal vasculitis and central retinal vein or artery occlusion; ² Cutaneous manifestations included erythema nodosum, pseudofolliculitis and papulopustular or acneiform lesions; ³ Articular manifestations included inflammatory arthralgia and arthritis; ⁴ Neurological manifestations included headache, pyramidal signs, behavioural and psychiatric alterations, meningeal signs, cerebellar signs, hearing impairment, hemichorea, memory impairment, gait disturbances, seizures, diplopia, and ataxia; ⁵ Gastrointestinal manifestations included abdominal pain, diarrhoea, bowel obstruction and bowel perforation.

phenotype, as earlier reports were from non-European populations^{3,4,9,10}. Importantly, although vascular involvement is considered a marker of poor prognosis, no statistically significant difference in mortality was detected. This may reflect sample size limitations or follow-up differences between studies.

To our knowledge, this is the first European registry-based study to identify independent predictors of vascular involvement in BD. Strengths include its long observational period, while limitations include its retrospective design and relatively small sample size. The small number of VBD events resulted in imprecise effect estimates, as reflected by the wide confidence intervals. In addition, ocular involvement encompassed retinal vasculitis, which may have contributed to an overestimation of its association with VBD by capturing a possibly shared underlying vasculitic process across distinct vascular beds. Our findings suggest that male sex and ocular manifestations at disease onset may identify patients at higher risk of VBD, but further studies are needed to validate these predictors and clarify their role in risk-stratified management.

REFERENCES

1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum*. 2013 Jan;65(1):1-11. <https://doi.org/10.1002/art.37715>
2. Emmi G, Bettiol A, Silvestri E, et al. Vascular Behçet's syndrome: an update. *Intern Emerg Med*. 2019 Aug;14(5):645-652. <https://doi.org/10.1007/s11739-018-1991-y>
3. Fei Y, Li X, Lin S, Song X, et al. Major vascular involvement in Behçet's disease: a retrospective study of 796 patients. *Clin Rheumatol*. 2013 Jun;32(6):845-52. <https://doi.org/10.1007/s10067-013-2205-7>
4. Düzgün N, Ateş A, Aydıntaş OT, Demir O, Olmez U. Characteristics of vascular involvement in Behçet's disease. *Scand J Rheumatol*. 2006 Jan-Feb;35(1):65-8. <https://doi.org/10.1080/03009740500255761>
5. Saadoun D, Wechsler B, Desseaux K, et al. Mortality in Behçet's disease. *Arthritis Rheum*. 2010 Sep;62(9):2806-12. <https://doi.org/10.1002/art.27568>
6. Seyahi E, Cakmak OS, Tutar B, et al. Clinical and Ultrasonographic Evaluation of Lower-extremity Vein Thrombosis in Behçet Syndrome: An Observational Study. *Medicine (Baltimore)*. 2015 Nov;94(44):e1899. <https://doi.org/10.1097/MD.0000000000001899>
7. International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. *J Eur Acad Dermatol Venereol*. 2014 Mar;28(3):338-47. <https://doi.org/10.1111/jdv.12107>
8. Ponte C, Khmelinskii N, Teixeira V, et al. Reuma.pt/vasculitis - the Portuguese vasculitis registry. *Orphanet J Rare Dis*. 2020; 15:110. <https://doi.org/10.1186/s13023-020-01381-0>
9. Houman MH, Neffati H, Braham A, et al. Behçet's disease in Tunisia. Demographic, clinical and genetic aspects in 260 patients. *Clin Exp Rheumatol*. 2007 Jul-Aug;25(4 Suppl 45):S58-64.
10. Tohmé A, Aoun N, El-Rassi B, Ghayad E. Vascular manifestations of Behçet's disease. Eighteen cases among 140 patients. *Joint Bone Spine*. 2003 Sep;70(5):384-9. [https://doi.org/10.1016/S1297-319X\(03\)00076-9](https://doi.org/10.1016/S1297-319X(03)00076-9)

SUPPLEMENTARY MATERIAL

SUPPLEMENTARY TABLE I. Patient-and disease-characteristics associated with vascular involvement in Behçet's disease-multivariable analysis

Variable	Univariable models OR (95%CI) (N=80-157)	Univariable models p-value	Multivariable model OR (95%CI) (N=153)
Male gender	3.59 (1.46-8.82)	0.005	3.99 (1.55-10.28)
Caucasian ancestry	0.57 (0.17-1.94)	0.379	†
Age at symptom onset (years)	0.99 (0.96-1.03)	0.758	‡
Oral ulcers at disease onset	1.37 (0.29-6.43)	0.690	†
Genital ulcers at disease onset	0.83 (0.33-2.10)	0.687	†
Ocular manifestations at disease onset	3.63 (1.27-10.33)	0.016	3.90 (1.29-11.72)
Cutaneous manifestations at disease onset	2.65 (1.06-6.67)	0.038	‡
Articular manifestations at disease onset	0.67 (0.14-3.14)	0.614	†
Neurological manifestations at disease onset	NA	NA	†
Gastrointestinal manifestations at disease onset	NA	NA	†
Constitutional symptoms at disease onset	0.54 (0.07-4.44)	0.567	†
Oral ulcer (ever)	NA	NA	†
Genital ulcers (ever)	1.22 (0.38-3.86)	0.741	†
Ocular manifestations (ever)	2.16 (0.90-5.20)	0.085	†
Cutaneous manifestations (ever)	4.28 (0.96-19.13)	0.057	†
Articular manifestations (ever)	0.55 (0.22-1.37)	0.197	†
Neurological manifestations (ever)	1.57 (0.52-4.70)	0.424	†
Gastrointestinal manifestations (ever)	0.72 (0.15-3.35)	0.670	†
Constitutional symptoms (ever)	2.81 (1.02-7.77)	0.046	‡
Positive pathergy test	1.09 (0.33-3.67)	0.885	†
Positive HLA-B51 haplotype	0.70 (0.19-2.61)	0.596	†

Variables selected for multivariable models if p-value <0.05 in univariable analysis.

† Not entered into multivariable analysis; ‡ Variables which were tested in the regression models but not retained after backward selection; NA, not applicable.